An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... injectable obesity drug Zepbound and diabetes medicine ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

We recently published a list of 10 Stocks To Buy Before They Split Next. In this article, we are going to take a look at ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...